NT (neurotensin) is an endogenous tridecapeptide neurotransmitter found in the central nervous system and gastrointestinal tract. One receptor for NT, NTS1, belongs to the GPCR (G-protein-coupled receptor) superfamily, has seven putative transmembrane domains, and is being studied by a range of singlemolecule, functional and structural approaches. To enable biophysical characterization, sufficient quantities of the receptor need to be expressed and purified in an active form. To this end, rat NTS1 has been expressed in Escherichia coli in an active ligand-binding form at the cell membrane and purified in sufficient amounts for structural biology studies either with or without fluorescent protein [YFP (yellow fluorescent protein) and CFP (cyan fluorescent protein)] fusions. Ligand binding has been demonstrated in a novel SPR (surface plasmon resonance) approach, as well as by conventional radioligand binding measurements. These improvements in production of NTS1 now open up the possibility of direct structural studies, such as solidstate NMR to interrogate the NT-binding site, EM (electron microscopy), and X-ray crystallography and NMR.
Introduction
GPCRs (G-protein coupled receptors) are a family of integral membrane proteins with seven transmembrane helices that are involved in a range of physiological processes, including cell-cell communication, sensory transduction, neuronal transmission and hormonal signalling [1] . Given that the majority of GPCR-targeted drugs in clinical practice (which represent more than 30% of all drugs) exert their actions on only 30 of the 750 identified human GPCRs, there is significant scope for further drug discovery in this field [1, 2] . Paradoxically, a structure of a ligand-binding GPCR is still awaited, and significant technical challenges hamper the routine expression and purification of this class of receptor in an active ligand-binding form.
NT (neurotensin) is an endogenous tridecapeptide neurotransmitter (Glu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-ProTyr-Ile-Leu) found in the central nervous system and gastrointestinal tract. It is responsible for the activation of the NTS (neurotensin receptor) family [3] . One such receptor, NTS1 (neurotensin receptor type 1), is a member of the GPCR superfamily [4] . Major effects of NT include analgesia, inhibition of food intake, modulation of dopaminergic systems and pituitary hormone secretion, and regulation of digestive function. It also acts as a trophic factor on human colon, pancreatic, prostate and lung cancer cell lines [5] . NTS1 therefore represents a possible target for the treatment of pain, obesity, schizophrenia and cancer. Here, the current status of our efforts to characterize NTS1 in preparation for structural studies is reported.
Optimized expression of NTS1
Rat NTS1 has been expressed previously as a protein fusion with MBP (maltose-binding protein) and TrxA (thioredoxin)-His 10 in the Escherichia coli DH5α strain [6] [7] [8] . Expression trials of the NTS1 construct were carried out in E. coli DH5α and BL21(DE3) cells, as well as C41(DE3) and C43(DE3)pREP4, two mutant strains derived from BL21(DE3) which have proved useful for the overexpression of several membrane and toxic proteins [9] . Cell pellets were detergent-solubilized, purified by IMAC (immobilized metal-ion-affinity chromatography) and assayed using a radioligand binding assay. The BL21(DE3) and C41(DE3) strains, induced with an IPTG (isopropyl β-D-thiogalactoside) concentration of 0.25 mM, produced the highest level of functional protein per litre of culture, yielding an approx. 3-fold improvement over DH5α. Increasing the IPTG concentration above 0.25 mM resulted in a decreased receptor yield in all cell types, suggesting that expression of the construct at higher rates has a toxicity effect (H. Atrill, P.J. Harding, E. Smith and A. Watts, unpublished work). 
Ligand binding demonstrated by radioligand binding, and SPR (surface plasmon resonance)
We measured the direct binding of detergent-solubilized NTS1 to immobilized NT ligand using SPR [10] . The redundancy of the seven N-terminal residues of NT in activating NTS1 was exploited by immobilizing N-terminally biotinylated NT to a streptavidin-coated surface. A rigorous specificity control, comprising a biotinylated scrambled peptide, was subtracted from the observed response to yield specific response curves ( Figure 1A) . Responses observed for the control surface were not significantly different from a blank The expression and purification of the receptor was followed using in-gel fluorescence [11] (Figure 3 ) and radioligand binding. The results indicated that the receptor is both fluorescent and able to bind ligand with high affinity throughout the purification. Given that GFP (green fluorescent protein) and its variants are not fluorescent when expressed on the periplasmic face of the membrane, or in inclusion bodies [12] , fluorescence confirms that the protein is being correctly targeted to the plasma membrane and is folding with the C-terminus of the receptor on the cytoplasmic side. The T43NTS1-CFP product was effectively purified to near homogeneity ( Figure 3 ) and a good correlation between receptor fluorescence and ligand-binding activity was observed during the purification. Further radioligand binding analysis confirmed the high affinity of purified T43NTS1-CFP for NT (K d = 0.9 ± 0.1 nM). This affinity compares well with affinities for the NT-NTS1 interaction reported previously [7] , indicating that the fusion with fluorescent protein does not alter the affinity of the receptor for NT. In addition, comparison of in-gel fluorescence (i.e. total receptor) with activity assay data provides a useful indication of the proportion of receptor which is able to bind ligand and will therefore allow further optimization of expression and purification procedures for NTS1, as well as other GPCRs.
Conclusions
Proteins of the GPCR family are predicted to comprise a large proportion of future drug targets. Consequently, further knowledge of the receptor structure, ligand binding and signal transduction mechanisms is required. Given that highresolution structural techniques, such as solid-state NMR [6, 13, 14] and crystallography, require milligram amounts of purified receptor in an active ligand-binding form, and the challenges associated with the (over)expression of GPCRs, any optimization of expression levels is clearly advantageous. Here we demonstrate optimization of GPCR expression and purification of NTS1, and demonstrate ligand-binding activity using both conventional radioligand binding assays and a novel application of SPR which enabled the NT-NTS1 interaction to be measured in real time. This approach has potential for application to other suitable GPCR systems, providing insights not only into the kinetics and mechanisms involved in ligand binding, but also into the search for novel ligands using high-throughput screening. Many GPCRs are thought to exist as dimers or oligomers [15] . The successful production of active CFP-and YFP-tagged NTS1 has provided us with valuable tools for the analysis of oligomerization by ensemble and single-molecule FRET (fluorescence resonance energy transfer)-based study of in vitro systems.
